Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2023)
40 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2023
Slide 1: N) N (e) N {e)) c a] a) oO = ‘w ra oO 3s
Fisher &Paykel HEALTHCARE N) N (e) N {e)) c a] a) oO = ‘w ra oO 3s ie) ra oO Ne © c Yn © 5 c Cc <
Slide 2: Online Help
Online Help Fisher &Paykel HEALTHCARE
Slide 3: Your Board
Your Board Scott St John Lewis Gradon Sir Michael Daniell Pip Greenwood Dy ) Lisa McIntyre Neville Mitchell Donal O’Dwyer Cather Simpson Fisher &Paykel HEALTHCARE
Slide 4: Agenda
Agenda *« Chair’s Address and Board Subcommittee Updates ¢ Managing Director and Chief Executive Officer’s Address * Financial Statements * Resolutions *« Voting * General Questions Fisher &Paykel HEALTHCARE
Slide 5: Scott St John, Board Chair
Scott St John Board Chair HEALTHCARE
Slide 6: FY2023 Financial Highlights
FY2023 Financial Highlights Operating Revenue $1.588 -6% Net Profit After Tax $250.3m -34% Total Dividend 40.5Q0cps $%
Slide 7: Hospital product group
Hospital product group iz Airvo 3 $1207.1M 42.5M Fisher &Paykel HEALTHCARE
Slide 8: Homecare product group
Homecare product group FY23 FP | Evora Full HOMECARE OPERATING REVENUE CONSTANT Guereniey 1) 1 —7 = PI Sa a FY19 FY20 FY21 FY22 FY23 Fisher &Paykel HEALTHCARE
Slide 9: Long Term Gross Margin and Operating Margin targets
Long Term Gross Margin target Long Term Operating Margin target
Slide 10: Dividend History
Dividend wo DIVIDEND HISTORY * Total dividend for the year increased by 3% to 40.5 cps “& * The company’s dividend ° reinvestment plan is available for +e . DG 30 eligible shareholders with a 3% & . discount 2° . 8 20 . ° 2 0 15 10 5 oO 2017 2018 2019 2020 2021 2022 2023 minterimcps mFinalcps Total
Slide 11: Scott St John, Board Chair
Scott St John Board Chair 1 Fisher&.Paykel HEALTHCARE
Slide 12: Your Board
Your Board Scott St John Lewis Gradon Sir Michael Daniell Pip Greenwood Dy ) Lisa McIntyre Neville Mitchell Donal O’Dwyer Cather Simpson Fisher &Paykel HEALTHCARE
Slide 13: Neville Mitchell
Neville Mitchell Audit & Risk Committee Chair Fisher&.Paykel HEALTHCARE
Slide 14: Lisa McIntyre
Lisa McIntyre People & Remuneration Committee Chair Fisher&.Paykel HEALTHCARE
Slide 15: Mike Daniell
Mike Daniell Quality, Safety & Regulatory Committee Chair Fisher&.Paykel HEALTHCARE
Slide 16: Scott St John, Board Chair
Scott St John Board Chair HEALTHCARE
Slide 17: Donal O'Dwyer
Donal O’Dwyer Director Fisher&.Paykel HEALTHCARE
Slide 18: Lewis Gradon
Lewis Gradon Managing Director and CEO Fisher&.Paykel HEALTHCARE
Slide 19: Connection video
Connection video
Slide 20: FY24 Financial Outlook
FY24 Financial Outlook First Half At 31 July 2023 exchange rates*, and assuming a continuation of trading conditions in the first four months, the company expects: * Operating revenue to be approximately $790 million. * Net profit after tax to be within the range of approximately $95 million to $105
Slide 21: Our growth opportunities
Our growth opportunitie HEALTHCARE
Slide 22: Applications outside of invasive ventilation
Invasive Noninvasive Hospital Home Respiratory Obstructive Sleep Respiratory Support Anesthesia Support Apnea Ventilation Ventilation Infant Care Surgical Applications outside of invasive ventilation
Slide 23: Long-term growth aspirations
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being indicative of levels of revenue or profitability in the short term.
Slide 24: Our progress over the last five years
Our progress over the last five years FY2019 FY2023 Change Comment ies with F&P people 38 53 39% * COVID-19 accelerated expansion Total people 4,547 6,564 44% People in Manufacturing & Operations 2,680 3,975 48% + Peaked at 4,989 in FY22 581 846 46% * Accelerated R&D investment 9% 1% 165bps 57ha 159
Slide 25: Gross margin and operating margin
GROSS MARGIN OPERATING (EBIT) MARGIN 70% 40% 60% 35% 30% 50% 25% 40% 20% 30% 15% 20% 10% 10% 5% 0% 0% FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 Long Term Gross Margin target Long Term Operating Margin target
Slide 26: Continuous improvement
Continuous improvement Projected total Cl initiatives for 2023 Our Global Cl Awards 2023 Total for 2019 Fisher & Paykel HEALTHCARE
Slide 27: Looking ahead
Looking ahead Ai FPA + Large, underpenetrated markets * Geographic expansion * Leveraging investment in R&D and infrastructure + Returning to target margins * Growing body of clinical evidence * Promising product pipeline * Long-term growth opportunities 27 Fisher &.Paykel HEALTHCARE
Slide 28: Scott St John, Board Chair
Scott St John Board Chair HEALTHCARE
Slide 29: Financial Statements
Financial Statements * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2023 annual report. ¢ There will be an opportunity to ask any general questions once all items on the agenda have been considered. Fisher &Paykel H
Slide 30: Resolutions
Resolutions Re-election of Pip Greenwood Auditor’s Remuneration Director’s Remuneration Issue of Performance Share Rights Issue of Options QRWN > Fisher &Paykel HEALTHCARE
Slide 31: How to Vote Online
How to Vote Online Notice of meeting Annual report Fisher &Paykel HEALTHCARE
Slide 32: Resolution 1: Re-election of Pip Greenwood
Resolution 1: Re-election of Pip Greenwood That Pip Greenwood, who retires by rotation and, being eligible, offers herself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 Fisher &Payke
Slide 33: Pip Greenwood
Pip Greenwood Director Fisher &Paykel HEALTHCARE
Slide 34: Resolution 1: Re-election of Pip Greenwood
Resolution 1: Re-election of Pip Greenwood That Pip Greenwood, who retires by rotation and, being eligible, offers herself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 Fisher &Payke
Slide 35: Resolution 2: Auditor's Remuneration
Resolution 2: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 Fisher &Paykel HEALTHCARE
Slide 36: Resolution 3: Director's Remuneration
Resolution 3: Director’s Remuneration That the maximum aggregate annual remuneration payable to non-executive Directors be increased by NZ$295,000 from NZ$1,455,000 to NZ$1,750,000 (plus GST as appropriate) be approved. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services
Slide 37: Resolution 4: Issue of Performance Share Rights
Resolution 4: Issue of Performance Share Rights That approval be given for the issue of up to 100,000 performance share rights under the Fisher & Paykel Healthcare 2022 Performance Share Rights Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to
Slide 38: Resolution 5: Issue of Options
Resolution 5: Issue of Options That approval be given for the issue of up to 190,000 options under the Fisher & Paykel Healthcare 2022 Share Option Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Mar
Slide 39: ykel
ykel HEALTHCARE Fisher &Par
Slide 40: Fisher &Paykel
Fisher &Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (2023) on 6ix